Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun 3:12:e17517.
doi: 10.7717/peerj.17517. eCollection 2024.

Effect of oral tryptamines on the gut microbiome of rats-a preliminary study

Mengyang Xu  1 , Andor J Kiss  2 , J Andrew Jones  3 , Matthew S McMurray  4 , Haifei Shi  1
Affiliations

Effect of oral tryptamines on the gut microbiome of rats-a preliminary study

Mengyang Xu et al. PeerJ. .

Abstract

Background: Psilocybin and related tryptamines have come into the spotlight in recent years as potential therapeutics for depression. Research on the mechanisms of these effects has historically focused on the direct effects of these drugs on neural processes. However, in addition to such neural effects, alterations in peripheral physiology may also contribute to their therapeutic effects. In particular, substantial support exists for a gut microbiome-mediated pathway for the antidepressant efficacy of other drug classes, but no prior studies have determined the effects of tryptamines on microbiota.

Methods: To address this gap, in this preliminary study, male Long Evans rats were treated with varying dosages of oral psilocybin (0.2 or 2 mg/kg), norbaeocystin (0.25 or 2.52 mg/kg), or vehicle and their fecal samples were collected 1 week and 3 weeks after exposure for microbiome analysis using integrated 16S ribosomal DNA sequencing to determine gut microbiome composition.

Results: We found that although treatment with neither psilocybin nor norbaeocystin significantly affected overall microbiome diversity, it did cause significant dose- and time-dependent changes in bacterial abundance at the phylum level, including increases in Verrucomicrobia and Actinobacteria, and decreases in Proteobacteria.

Conclusion and implications: These preliminary findings support the idea that psilocybin and other tryptamines may act on the gut microbiome in a dose- and time-dependent manner, potentially identifying a novel peripheral mechanism for their antidepressant activity. The results from this preliminary study also suggest that norbaeocystin may warrant further investigation as a potential antidepressant, given the similarity of its effects to psilocybin.

Keywords: Actinobacteria; Gut microbiome; Norbaeocystin; Proteobacteria; Psilocybin; Rat; Verrucomicrobia.

PubMed Disclaimer

Conflict of interest statement

J. Andrew Jones is a significant stakeholder at PsyBio Therapeutics. PsyBio Therapeutics has licensed tryptamine biosynthesis-related technology from Miami University. J. Andrew Jones and Matthew S. McMurray are co-inventors on several patent applications related to tryptamine biosynthesis and the impacts of tryptamines on animal behavior. All other authors declare no conflicts of interest.

Figures

Figure 1
Figure 1. Effects of psilocybin and norbaeocystin treatment on microbial diversity.
Effects of low dosage 0.2 mg/kg of psilocybin (P-low), high dosage 2 mg/kg of psilocybin (P-high), low dosage 0.25 mg/kg of norbaeocystin (N-low), and high dosage 2.52 mg/kg of norbaeocystin (N-high) on taxonomic composition of bacterial communities at the phylum level 1 week after treatment (A) or 3 weeks after treatment (B). Effects of P-low and P-high (C) and N-low and N-high (D) on microbial diversity, measured by Shannon diversity index. Significant differences in diversity at the phylum level between groups were determined by a two-way ANOVA followed by FDR-corrected post hoc comparisons analysis. p < 0.05 was considered statistically significant.
Figure 2
Figure 2. Effects of psilocybin and norbaeocystin treatment on abundance of major microbial phyla at the phylum level and their ratio.
Effects of low dosage 0.2 mg/kg of psilocybin (P-low) and high dosage 2 mg/kg of psilocybin (P-high) (A), low dosage 0.25 mg/kg of norbaeocystin (N-low) and high dosage 2.52 mg/kg of norbaeocystin (N-high) (B) on Firmicutes abundance. Effects of P-low and P-high (C) and N-low and N-high (D) on Bacteroidetes abundance. Effects of P-low and P-high (E) and N-low and N-high (F) on the Firmicutes/Bacteroidetes ratio. Significant differences in relative abundance of Firmicutes or Bacteroidetes bacterial population and the Firmicutes/Bacteroidetes ratio between groups were determined by a two-way ANOVA followed by FDR-corrected post hoc comparisons analysis. p < 0.05 was considered statistically significant. *Indicated statistical significance.
Figure 3
Figure 3. Effects of psilocybin and norbaeocystin treatment on abundance of minor microbial phyla at the phylum level.
Effects of low dosage 0.2 mg/kg of psilocybin (P-low) and high dosage 2 mg/kg of psilocybin (P-high) (A), low dosage 0.25 mg/kg of norbaeocystin (N-low) and high dosage 2.52 mg/kg of norbaeocystin (N-high) (B) on Proteobacteria abundance. Effects of P-low and P-high (C) and N-low and N-high (B) on Actinobacteria abundance. Effects of P-low and P-high (E) and N-low and N-high (F) on Verrucomicrobia abundance. Effects of P-low and P-high (G) and N-low and N-high (H) on Tenericutes abundance. Significant differences in relative abundance of bacterial population were determined by a two-way ANOVA followed by FDR-corrected post hoc comparisons analysis. p < 0.05 was considered statistically significant. *Indicated statistical significance.
See this image and copyright information in PMC

References

    1. Adams AM, Anas NA, Sen AK, Hinegardner-Hendricks JD, O’Dell PJ, Gibbons WJ, Jr., Flower JE, McMurray MS, Jones JA. Development of an E. coli-based norbaeocystin production platform and evaluation of behavioral effects in rats. Metabolic Engineering Communications. 2022;14:e00196. doi: 10.1016/j.mec.2022.e00196. - DOI - PMC - PubMed
    1. Adams AM, Kaplan NA, Wei Z, Brinton JD, Monnier CS, Enacopol AL, Ramelot TA, Jones JA. In vivo production of psilocybin in E. coli. Metabolic Engineering. 2019;56:111–119. doi: 10.1016/j.ymben.2019.09.009. - DOI - PubMed
    1. Anderson JR, Carroll I, Azcarate-Peril MA, Rochette AD, Heinberg LJ, Peat C, Steffen K, Manderino LM, Mitchell J, Gunstad J. A preliminary examination of gut microbiota, sleep, and cognitive flexibility in healthy older adults. Sleep Medicine. 2017;38(6315):104–107. doi: 10.1016/j.sleep.2017.07.018. - DOI - PMC - PubMed
    1. Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, Fernandes GR, Tap J, Bruls T, Batto J-M, Bertalan M, Borruel N, Casellas F, Fernandez L, Gautier L, Hansen T, Hattori M, Hayashi T, Kleerebezem M, Kurokawa K, Leclerc M, Levenez F, Manichanh C, Nielsen HB, Nielsen T, Pons N, Poulain J, Qin J, Sicheritz-Ponten T, Tims S, Torrents D, Ugarte E, Zoetendal EG, Wang J, Guarner F, Pedersen O, de Vos WM, Brunak S, Doré J, Antolín M, Artiguenave F, Blottiere HM, Almeida M, Brechot C, Cara C, Chervaux C, Cultrone A, Delorme C, Denariaz G, Dervyn R, Foerstner KU, Friss C, van de Guchte M, Guedon E, Haimet F, Huber W, van Hylckama-Vlieg J, Jamet A, Juste C, Kaci G, Knol J, Kristiansen K, Lakhdari O, Layec S, Le Roux K, Maguin E, Mérieux A, Melo Minardi R, M’Rini C, Muller J, Oozeer R, Parkhill J, Renault P, Rescigno M, Sanchez N, Sunagawa S, Torrejon A, Turner K, Vandemeulebrouck G, Varela E, Winogradsky Y, Zeller G, Weissenbach J, Ehrlich SD, Bork P, Meta HITC. Enterotypes of the human gut microbiome. Nature. 2011;473(7346):174–180. doi: 10.1038/nature09944. - DOI - PMC - PubMed
    1. Banerjee S, Schlaeppi K, van der Heijden MGA. Keystone taxa as drivers of microbiome structure and functioning. Nature Reviews Microbiology. 2018;16(9):567–576. doi: 10.1038/s41579-018-0024-1. - DOI - PubMed